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Abstract 
A woman with heavy pre-treated ovarian cancer sought consultation regarding 
additional treatments. The case raises the vexing question of whether there may be a 
time in the course of the disease process where it is most appropriate to state further 
anti-neoplastic therapy will not be of clinical utility. 
Background 
There have been complex discussions recently in both the medical literature and the 
lay press regarding the relative value and clinical utility of new, and often quite novel, 
pharmaceutical agents employed as treatment of advanced cancers. It is reasonable to 
acknowledge that much of this debate has focused on the critically important issue of the 
relative cost-effectiveness of such therapies, whether that cost is to be borne by a 
governmental agency, an employer, a third-party insurer, or the individual patient/family 
[1]. 
Further, there is also the question of the potential toxicity of such treatments, 
particularly in the setting of older cancer patients with pre-existing co-morbid medical 
conditions (e.g. past history of a myocardial infarction, diabetic renal dysfunction, etc.). 
Here the issue is the valid concern that any theoretical potential for benefit must be 
weighed against the probability the therapy may produce harm. 
Less often heard in these debates is perhaps an even more vexing question, that of the 
fundamental right of cancer patients to decide that they want to initiate or continue 
therapy, independent of the fact an objective external observer reviewing the situation  
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may declare that based on existing evidence of potential benefit such a decision must be 
considered to be extremely unwise or outright irrational. Assuming the cost of additional 
therapy is not a determining factor (e.g. the family will pay), and the risk of serious 
toxicity is not an overwhelming concern, should patients be permitted to simply declare 
they wish to receive a specific treatment that may be available for their condition? Or does 
a physician have an obligation in certain circumstances to state that further antineoplastic 
drug treatment should not continue due to the absence of a realistic potential for any 
clinical benefit? 
A requested consultation involving a heavily pre-treated ovarian cancer patient 
represents a poignant example of this ethical dilemma.  
Case Report 
A 43-year-old female presented with ascites and was found to have a malignancy (papillary 
adenocarcinoma) diffusely involving the peritoneal cavity. The serum CA-125 antigen level was 8,000 
IU/l. The patient experienced an excellent initial response to primary platinum-based chemotherapy (2 
cycles of cisplatin/cyclophosphamide followed by 6 cycles of carboplatin/paclitaxel) with a decline in the 
CA-125 antigen level to 148 IU/l. Treatment was continued with 4 cycles of a carboplatin/gemcitabine 
regimen, but the tumor marker increased to 400 IU/l. At this point in time radiographic imaging of the 
peritoneal cavity revealed no tumor masses.  
However, following 2 additional cycles of carboplatin/cyclophosphamide the CA-125 had increased 
to >1,000 IU/l, ascites returned, and there was evidence of macroscopic disease within the peritoneal 
cavity. The patient was treated with a program of pelvic radiation and concurrent weekly docetaxel plus 
bevacizumab. There was a modest decline in the CA-125 antigen level (<50%) and ascites appeared to 
decrease somewhat. Treatment was continued with carboplatin, docetaxel and bevacizumab. Following 
a slight increase in the CA-125 antigen level, treatment was changed to cisplatin, topotecan and 
bevacizumab, and subsequently to oxaliplatin, irinotecan and bevacizumab. At the time of clinical 
progression a laparoscopy was performed which revealed diffuse small implants (each <1 cm in 
maximum diameter) throughout the peritoneal cavity. The patient was subsequently treated with 
liposomal doxorubicin and then with a program of paclitaxel and vinorelbine. Unfortunately, there was 
further evidence of disease progression on this most recent regimen. 
However, the patient maintained a good performance status, was essentially asymptomatic at the 
time of the consultation, and strongly desired additional treatment. 
Discussion 
At the time of the request for input into possible future therapeutic options, this 
patient had already received 10 chemotherapy regimens that included a total of 11 
different antineoplastic agents. She had also undergone pelvic radiation. While her overall 
clinical condition was fortunately quite reasonable, and there were no specific medical 
contraindications to continuing chemotherapy, this case raises the possibly 
uncomfortable question that perhaps the issue to be addressed in this situation was not 
‘what drug to give next’, but rather whether it was appropriate that any additional 
antineoplastic agents should be administered. 
As a recent commentary written by physicians in a medical intensive care unit who 
were caring for an elderly woman with advanced multiple myeloma eloquently describes 
[2], it can be very difficult for some patients with progressive malignancies (and their 
families) to accept the concept of withholding further management strategies directed at 
treating the cancer, as this decision clearly implies the acceptance that the cancer will 
result in the death of the patient. By continuing to focus ones energies on ‘fighting the  
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cancer’, some individuals appear to be able to delay the consideration of what are 
apparently unacceptably distressing thoughts and feelings.  
Unfortunately, the end result of this avoidance may be side effects, whether relatively 
minor or more severe, and the very real potential for a more rapid deterioration in overall 
quality of life than would have occurred in the absence of treatment strategies that have 
no realistic chance of producing a favorable impact on the future course of the illness. 
Avoidance of what is emotionally and psychologically difficult may lead, even if 
completely inadvertent, to serious harm. 
It is important to acknowledge that not all treatments considered for administration in 
individuals with similar characteristics to those described in this case report will result in 
major side effects (e.g. cisplatin-induced neuropathy/hearing loss, etoposide-associated 
secondary acute leukemia). However, even more modest toxicities (e.g. mild nausea, 
moderate fatigue) may negatively influence a patient’s activities of daily living and the 
enjoyment of her/his remaining time with family and friends. 
An additional component of this discussion is the complex and controversial issue of 
medical futility. It is generally accepted that physicians are not ethically required to offer, 
or participate in, care that is medically futile, even if requested or demanded by patients 
and/or their families [3–5]. In this context, ‘medically futile care’ usually refers to the 
complete absence of evidence a particular intervention can achieve the desired physiologic 
effects (e.g. a procedure designed to restore heart function following a prolonged cardiac 
arrest), rather than the absence of a reasonable chance the specified intervention will 
improve quality of life or extend survival. 
It is appropriate, in fact mandatory, to declare that individual physicians should never 
be permitted to ‘play God’ and substitute their personal value systems regarding the utility 
of medical procedures or anti-cancer therapies [6]. 
However, it can similarly be suggested that based on carefully considered objective 
data, the oncology community (perhaps represented by internationally recognized and 
respected cancer organizations), with strong input from nonmedical sources (e.g. patient 
advocates, biomedical ethicists, governmental/regulatory officials, members of the clergy), 
can develop rational statements regarding what may be considered in specific 
circumstances to be medically futile therapy when delivered to directly impact the clinical 
course of the cancer. Under such circumstances, when an expressed desire for more 
treatment is beyond the realm of a rational decision, one can legitimately argue that 
further therapy is not medically indicated and need not be provided. 
It is critical to acknowledge here that this discussion has nothing to do with the 
delivery of known effective therapies designed to palliate specific (e.g. external beam 
radiation directed to a painful pelvic sidewall mass) or more general malignancy-
associated symptoms (e.g. narcotic analgesia for pain control). 
Clearly, the decision by patients to continue or stop antineoplastic drug therapy is 
extremely complex, emotionally laden, and not formula driven. While it is not possible to 
provide a simple roadmap for oncologists as to when they need to definitively declare, or 
at least strongly state, that further treatment directed toward shrinking the tumor or 
preventing an established pattern of progression is futile, it is also reasonable to conclude 
that in certain settings this is a role a caring and compassionate physician must consider 
assuming. 
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